Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6atac small nuclear (RNU6ATAC) is a small non-coding nuclear RNA (snRNA) that is a critical catalytic component of the minor (U12-dependent) spliceosome, a specialized cellular machine responsible for the splicing of a rare subclass of introns (minor or U12-type introns) from precursor messenger RNAs (pre-mRNAs)[1][2][3][4]. The minor spliceosome consists of distinct snRNAs (U11, U12, U4atac, U6atac, U5), and U6atac is essential for the catalytic core of this complex[1][2][3]. U6atac is highly unstable compared to other snRNAs and serves as a rate-limiting factor in the splicing of minor introns, which affects expression of hundreds of genes involved in diverse and critical cellular pathways[1]. Its abundance can be regulated by cellular stress pathways such as p38MAPK, thus influencing gene expression post-transcriptionally[1]. Although dysregulation of minor intron splicing, via changes in U6atac, impacts pathways important in diseases (e.g., tumor suppressor expression, cytokine regulation), RNU6ATAC is not itself a classic therapeutic target such as a receptor, enzyme, or transporter, and no drugs are known to directly interact with it[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear (RNU6ATAC).